Compare GWAV & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWAV | XRTX |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Pharmaceuticals and Biotechnology |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.9M |
| IPO Year | 2014 | 2018 |
| Metric | GWAV | XRTX |
|---|---|---|
| Price | $5.11 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.1K | 8.1K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,098,036.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 116184.26 | N/A |
| 52 Week Low | $2.39 | $0.35 |
| 52 Week High | $24.00 | $3.60 |
| Indicator | GWAV | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.56 | 50.98 |
| Support Level | $5.15 | $1.99 |
| Resistance Level | $6.24 | $2.29 |
| Average True Range (ATR) | 0.56 | 0.19 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 69.74 | 43.79 |
Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia, Ohio, & North Carolina. At these facilities, the company collects, classifies, & processes appliances, construction materials, end-of-life vehicles, boats, & industrial machinery. The company processes these items by crushing, shearing, shredding, separating, & sorting into smaller pieces & categorizes these recycled ferrous, nonferrous, & mixed metal pieces based on density & metal type before sale. For scrap cars, it removes the catalytic converters, aluminum wheels, & batteries for separate processing & sale before shredding the vehicle. The company is organized into three operating segments: Scrap Metal Recycling, Hauling, & Other (comprised of rental income).
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.